IPNews® – GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. were accused in a new class action in New Jersey federal court on Thursday of striking illegal deals to delay the entry of generic versions of Glaxo’s epilepsy drug Lamictal to the market until Glaxo’s patent for it expired.
Glaxo sued Teva after it filed an